Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,803 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04514692 | Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging | terminated | Phase 1 / Phase 2 | 7 | Stanford UniversityOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT04875806 | A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 40 | NextCure, Inc.INDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT03610490 | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT03764540 | Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide(CABPOSTAAT) | terminated | Phase 2 | 57 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT04556617 | PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | terminated | Phase 1 / Phase 2 | 19 | Opna Bio LLCINDUSTRY | 2 | Apr 8, 2025 | clinicaltrials |
| NCT03527264 | BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer | terminated | Phase 2 | 4 | Brown UniversityOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors | terminated | Phase 2 | 54 | Elevation OncologyINDUSTRY | 4 | Apr 3, 2025 | clinicaltrials |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | terminated | Phase 1 / Phase 2 | 222 | Kymab LimitedINDUSTRY | 6 | Apr 2, 2025 | clinicaltrials |
| NCT02641639 | FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer | terminated | Phase 2 / Phase 3 | 70 | Mateon TherapeuticsINDUSTRY | 3 | Mar 24, 2025 | clinicaltrials |
| NCT04382898 | PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)(PRO-MERIT) | terminated | Phase 1 / Phase 2 | 75 | BioNTech SEINDUSTRY | 4 | Mar 20, 2025 | clinicaltrials |
| NCT04298983 | Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer(RAD 1805) | terminated | Phase 2 | 9 | University of Alabama at BirminghamOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06257758 | A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors | terminated | Phase 1 / Phase 2 | 6 | Valerio TherapeuticsINDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | terminated | Phase 2 | 205 | Seagen Inc.INDUSTRY | 6 | Mar 10, 2025 | clinicaltrials |
| NCT04750941 | Study of Copanlisib and Ketogenic Diet | terminated | Phase 2 | 1 | Columbia UniversityOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT05075577 | EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC | terminated | Phase 1 / Phase 2 | 77 | ESSA PharmaceuticalsINDUSTRY | 3 | Feb 28, 2025 | clinicaltrials |
| NCT05501548 | Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer | terminated | Phase 2 | 4 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT03891576 | Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)(Newton) | terminated | Phase 2 | 83 | Mario Negri Institute for Pharmacological ResearchOTHER | 2 | Jan 17, 2025 | clinicaltrials |
| NCT04951492 | Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma | terminated | Phase 2 | 2 | University of WashingtonOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT03099499 | Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer | terminated | Phase 2 | 19 | Fox Chase Cancer CenterOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | terminated | Phase 1 / Phase 2 | 15 | Aminex Therapeutics, Inc.INDUSTRY | 2 | Dec 24, 2024 | clinicaltrials |
| NCT04939701 | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants | terminated | Phase 1 / Phase 2 | 16 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT05917470 | A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. | terminated | Phase 1 / Phase 2 | 21 | Oncternal Therapeutics, IncINDUSTRY | 2 | Dec 11, 2024 | clinicaltrials |
| NCT04826198 | Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months(REVOCAN) | terminated | Phase 1 / Phase 2 | 13 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT05261490 | Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 10 | PfizerINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT04493619 | PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer | terminated | Phase 1 / Phase 2 | 37 | Opna Bio LLCINDUSTRY | 2 | Nov 4, 2024 | clinicaltrials |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT03177187 | Combination Study of AZD5069 and Enzalutamide.(ACE) | terminated | Phase 1 / Phase 2 | 30 | Institute of Cancer Research, United KingdomOTHER | 2 | Sep 26, 2024 | clinicaltrials |
| NCT03493464 | BR55 in Characterization of Ovarian Lesions | terminated | Phase 2 | 14 | Bracco Diagnostics, IncINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03644342 | Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix(NIVIX) | terminated | Phase 1 / Phase 2 | 4 | Michelle S LudwigOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT00321698 | Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer | terminated | Phase 1 / Phase 2 | 25 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT04248153 | Optimal Timing of BR55 CEUS of the Ovaries | terminated | Phase 2 | 3 | Bracco Diagnostics, IncINDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT00819169 | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | terminated | Phase 1 / Phase 2 | 89 | NantCell, Inc.INDUSTRY | 0 | Aug 20, 2024 | clinicaltrials |
| NCT04377087 | Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer | terminated | Phase 2 | 3 | Sarah E TaylorOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Tango Therapeutics, Inc.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05001282 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) | terminated | Phase 1 / Phase 2 | 79 | Elucida OncologyINDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | terminated | Phase 1 / Phase 2 | 3 | NantCell, Inc.INDUSTRY | 1 | Aug 6, 2024 | clinicaltrials |
| NCT03323398 | Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 79 | ModernaTX, Inc.INDUSTRY | 1 | Jul 31, 2024 | clinicaltrials |
| NCT04408599 | A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 46 | NextCure, Inc.INDUSTRY | 1 | Jul 25, 2024 | clinicaltrials |
| NCT04159896 | ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer | terminated | Phase 2 | 10 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT03439085 | DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers | terminated | Phase 2 | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT03770455 | Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC | terminated | Phase 2 | 8 | Jodi Layton, MDOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT03690141 | An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer | terminated | Phase 2 | 16 | Effector TherapeuticsINDUSTRY | 1 | Jun 21, 2024 | clinicaltrials |
| NCT03367871 | Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer | terminated | Phase 2 | 17 | University of MiamiOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT04458311 | Abiraterone Acetate in Combination With Tildrakizumab(ACTIon) | terminated | Phase 1 / Phase 2 | 13 | Institute of Cancer Research, United KingdomOTHER | 2 | Apr 25, 2024 | clinicaltrials |
| NCT05538624 | A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary | terminated | Phase 1 / Phase 2 | 14 | Avenge Bio, IncINDUSTRY | 1 | Apr 24, 2024 | clinicaltrials |
| NCT01393119 | Phase II, Dose Finding Study of GTx-758 | terminated | Phase 2 | 77 | GTxINDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT03311334 | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 47 | Sumitomo Pharma America, Inc.INDUSTRY | 2 | Apr 18, 2024 | clinicaltrials |
| NCT03810105 | A Study of Olaparib and Durvalumab in Prostate Cancer | terminated | Phase 2 | 5 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT04743999 | Evaluation of Outcomes in Women Undergoing Multimodality Treatment for Advanced Stage Endometrial Carcinoma | terminated | Phase 2 | 9 | Henry Ford Health SystemOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT00889733 | Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer(OVHM-01) | terminated | Phase 1 / Phase 2 | 9 | University Health Network, TorontoOTHER | 1 | Mar 26, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Apr 23, 2025source: clinicaltrials